Publications published since 2010 by Jon Amund Kyte

34 publications found

Publications 2023

1. Beck C, Casey NP, Persiconi I, Moharrami NN, Sike A, Jin Y, Kyte JA (2023)
   Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
   Biomedicines, 11 (2)
   DOI 10.3390/biomedicines11020459, PubMed 36830995
2. Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A (2023)
   How I treat endocrine-dependent metastatic breast cancer
   ESMO Open, 8 (2), 100882 (in press)
   DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375

Publications 2022

1. Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
   Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
   Cancers (Basel), 14 (19)
   DOI 10.3390/cancers14194859, PubMed 36230782
2. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
3. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
4. Jin Y, Lorvik KB, Jin Y, Beck C, Sike A, Persiconi I, Kvaløy E, Saatcioglu F, Dunn C, Kyte JA (2022)
   Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
   Mol Ther Oncolytics, 26, 189-206
   DOI 10.1016/j.omto.2022.06.007, PubMed 35860008
5. Kyte JA (2022)
   Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
   Cancers (Basel), 14 (3)
   DOI 10.3390/cancers14030571, PubMed 35158839
6. Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
   Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
   Nat Med, 28 (12), 2573-2583
   DOI 10.1038/s41591-022-02126-1, PubMed 36482103
7. Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
   Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
   ESMO Open, 7 (5), 100588
   DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

1. Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
   Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
   Int J Cancer, 150 (1), 100-111
   DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

1. Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
   Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
   Front Immunol, 11, 572172
   DOI 10.3389/fimmu.2020.572172, PubMed 33324397
2. Casey NP, Kyte JA, Fujiwara H (2020)
   Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
   Methods Mol Biol, 2115, 327-349
   DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409
3. Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
   ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
   J Transl Med, 18 (1), 269
   DOI 10.1186/s12967-020-02421-w, PubMed 32620163
4. Kyte JA, Røssevold A, Falk RS, Naume B (2020)
   ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
   J Transl Med, 18 (1), 252
   DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Publications 2019

1. Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
   Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
   Oncoimmunology, 8 (4), e1565236
   DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
2. Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
   An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
   Nat Commun, 10 (1), 5499
   DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

1. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
   Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
   Adv Radiat Oncol, 3 (2), 130-138
   DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
2. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
   Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
   Oncoimmunology, 8 (2), e1537691
   DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
3. Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
   Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
   Oncoimmunology, 7 (11), e1457598
   DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
4. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
   Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
   Cancer Immunol Res, 6 (4), 467-480
   DOI 10.1158/2326-6066.CIR-17-0207, PubMed 29459477

Publications 2017

1. Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
   Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
   Breast Cancer Res, 19 (1), 120
   DOI 10.1186/s13058-017-0911-9, PubMed 29137653

Publications 2016

1. Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A (2016)
   Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
   Ecancermedicalscience, 10, 691
   DOI 10.3332/ecancer.2016.691, PubMed 27994647
2. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin Transl Immunology, 5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
3. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
   T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
   Oncoimmunology, 5 (12), e1249090
   DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
4. Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
   Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
   Oncoimmunology, 5 (11), e1232237
   DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Publications 2015

1. Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
   Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
   Gene Ther, 22 (5), 391-403
   DOI 10.1038/gt.2015.4, PubMed 25652098
2. Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
   Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
   Cancer Immunol Immunother, 64 (12), 1609-21
   DOI 10.1007/s00262-015-1766-5, PubMed 26498005

Publications 2014

1. Gjersvik P, Kyte JA (2014)
   [Field cancerization of skin and mucous membranes]
   Tidsskr Nor Laegeforen, 134 (18), 1769
   DOI 10.4045/tidsskr.13.1454, PubMed 25273254

Publications 2013

1. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
   Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
   Int J Cancer, 134 (1), 102-13
   DOI 10.1002/ijc.28338, PubMed 23784959
2. Kyte JA (2013)
   [The cancer riddle is outdated]
   Tidsskr Nor Laegeforen, 133 (18), 1907
   DOI 10.4045/tidsskr.13.1037, PubMed 24084948

Publications 2011

1. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
   Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
   Clin Cancer Res, 17 (21), 6847-57
   DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169
2. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
   Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
   Clin Cancer Res, 17 (13), 4568-80
   DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Publications 2010

1. Kyte JA (2010)
   Third International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD 2009)
   Expert Rev Vaccines, 9 (2), 119-23
   DOI 10.1586/erv.09.157, PubMed 20109021
2. Kyte JA (2010)
   [We know more than we can understand]
   Tidsskr Nor Laegeforen, 130 (22), 2217
   DOI 10.4045/tidsskr.10.1000, PubMed 21109831